Medicare rules, CMS guidance, reimbursement, and benefit changes affecting patients and providers.
CMS and the FDA have created a new Medicare coverage pathway aimed at speeding access to certain breakthrough medical devices. The first practical effect is a faster route to a proposed Medicare coverage decision after FDA authorization, but many details still depend on implementation.
CMS has proposed a rule that would extend electronic prior authorization to certain drugs covered under a medical benefit. It would not take effect right away, and most patients would not feel the change until at least 2027 if the rule is finalized.
CMS says it began enforcing updated hospital price transparency rules on April 1, 2026, but patients should still treat posted prices as a starting point.
Original Medicare can pay for some hearing tests in 2026, but hearing aids are still usually excluded. Here is what changed, what did not, and what to compare.
As of April 1, 2026, CMS is enforcing updated hospital price transparency rules. The files may be easier to compare, but they still are not your final bill.
Current U.S. guidance says adults 75 and older who have never had an RSV shot should get one dose now, with no repeat dose advised at this time.
A new Medicare study suggests the $35 insulin cap is lowering patients’ costs. But supplies, other diabetes expenses, and gaps outside Medicare still matter.
A new CMS proposal could close a pathway for states to add adult dental benefits to ACA Marketplace plans in 2027, leaving many shoppers with separate coverage.
A knee arthritis study points to real symptom relief with semaglutide, but Medicare access still depends on why it is prescribed and who qualifies.
As of April 2026, the federal nursing home staffing rule is no longer being phased in. Here’s what it would have required and what families should watch now.
Medicare’s 2026 physician payment rule may improve care coordination, telehealth, and home visits, but local staffing and practice finances still matter.
Some plans now have to post 2025 prior-authorization data. Here is what patients and clinicians can learn from the new CMS reports, and what they cannot.
Minnesota’s Medicaid funding deferral does not automatically end coverage. The closer short-term risk is provider payment strain, tighter oversight, and access friction.
CMS began enforcing updated hospital price transparency requirements on April 1, 2026. Here’s what patients can actually compare before planned care, what changed in hospital price files, and why the posted number is still not a final bill.
Medicare changed how it pays for many skin substitute products used in diabetic foot ulcers in 2026, but it did not broadly stop covering care. Here’s what the change may mean for access, treatment conversations, and when to seek help.
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
Osteoporosis is often treated like a women’s issue, but men can develop it too and may be diagnosed only after a serious fracture. Here is who should ask about a DXA bone density scan, how national policy differs from specialty guidance, and what Medicare may or may not cover.
CMS has started a limited Original Medicare pilot in six states that uses technology vendors and clinician review for a narrow set of services. Here’s what WISeR does, what has not changed, how reviews and appeals work, and why some experts worry about delays.
As of April 2, 2026, nothing changes at the pharmacy yet for Medicare patients taking Xeljanz, Orencia, Cosentyx, or Cimzia. What changed is that Medicare has selected these drugs for its third negotiation cycle, manufacturers are participating, and any negotiated prices would not begin until January 1, 2028.
A November 6, 2025 study found that hearing loss was common among Hispanic Medicare beneficiaries age 65 and older, but hearing aid use was much lower. Here is what the study found, what Original Medicare does and does not cover, where OTC hearing aids may fit, and when it is time to get tested.
CMS has announced first-year awards in all 50 states under a five-year rural health program. The funding could help states recruit, train, and keep more clinicians, but federal workforce data show rural primary care shortages remain deep and patient-facing relief is likely to take time.
Federal enforcement of updated hospital price transparency requirements begins April 1, 2026. That may make some hospital price listings more useful for planned care, but posted prices still are not the same as your final out-of-pocket bill.
End of content
End of content
